David A. Siegel Aerovate Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 110,900 shares of AVTE stock, worth $294,994. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110,900
Previous 69,800
58.88%
Holding current value
$294,994
Previous $115,000
100.87%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AVTE
# of Institutions
78Shares Held
28.1MCall Options Held
116KPut Options Held
26.6K-
Ra Capital Management, L.P. Boston, MA9.19MShares$24.5 Million0.27% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$10 Million0.74% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.96 Million0.61% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.79 Million0.46% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$3.75 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $65M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...